Progress in the development of a therapeutic vaccine for breast cancer

References

• ColeyWBThe treatment of malignant tumors by repeated inoculations of Erysipelas: With a report of ten original casesAm J Med Sci18931055487
   Google Scholar
• GoedegebuurePSWatsonMAViehlCTFlemingTPMammaglobin-based strategies for treatment of breast cancerCurr Cancer Drug Targets20044653154215462037
   PubMed Web of Science ®Google Scholar
• BurnetFMImmunological aspects of malignant diseaseLancet196717501117111744165129
   PubMed Web of Science ®Google Scholar
• ShankaranVIkedaHBruceATIFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicityNature200141068321107111110.1038/3507412211323675
   PubMed Web of Science ®Google Scholar
• AndersonKSTumor vaccines for breast cancerCancer Invest200927436136810.1080/0735790080257442119358018
   PubMed Web of Science ®Google Scholar
• HiganoCSSchellhammerPFSmallEJIntegrated data from 2 randomized, double-blind, placebo-controlled, phase III trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancerCancer2009115163670367910.1002/cncr.2442919536890
   PubMed Web of Science ®Google Scholar
• SmallEJSchellhammerPFHiganoCSPlacebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerJ Clin Oncol200624193089309410.1200/JCO.2005.04.525216809734
   PubMed Web of Science ®Google Scholar
• SchellhammerPFHiganoCSBergerERA randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC)American Urological Association, Annual Meeting2009
   Google Scholar
• Solal-CelignyPRoyPColombatPFollicular lymphoma international prognostic indexBlood200410451258126510.1182/blood-2003-12-443415126323
   PubMed Web of Science ®Google Scholar
• SchusterSJNeelapuSSGauseBLIdiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results[Meeting Abstracts] J Clin Oncol200927Suppl 182
   Web of Science ®Google Scholar
• RosenbergSAYangJCWhiteDESteinbergSMDurability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating responseAnn Surg199822833073199742914
   PubMed Web of Science ®Google Scholar
• RosenbergSAYangJCSchwartzentruberDJImmunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanomaNat Med1998433213279500606
   PubMed Web of Science ®Google Scholar
• SchwartzentruberDJLawsonDRichardsJA phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanomaJ Clin Oncol200927Suppl18
   Google Scholar
• EmensLAAsquithJMLeathermanJMTimed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation [Breast Cancer]Journal of Clinical Oncology2009273559115918 http://jco.ascopubs.org10.1200/JCO.2009.23.349419805669
   PubMed Web of Science ®Google Scholar
• DisisMLShiotaFMCheeverMAHuman HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ‘self’ tumour antigensImmunology19989321921999616368
   PubMed Web of Science ®Google Scholar
• CheeverMAAllisonJPFerrisASThe prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational researchClin Cancer Res200915175323533710.1158/1078-0432.CCR-09-073719723653
   PubMed Web of Science ®Google Scholar
• BargmannCIHungMCWeinbergRAThe neu oncogene encodes an epidermal growth factor receptor-related proteinNature1986319605022623010.1038/319226a03945311
   PubMed Web of Science ®Google Scholar
• CoussensLYang-FengTLLiaoYCTyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogeneScience19852304730113211392999974
   PubMed Web of Science ®Google Scholar
• PressMFCordon-CardoCSlamonDJExpression of the HER-2/neu proto-oncogene in normal human adult and fetal tissuesOncogene1990579539621973830
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience198924449057077122470152
   PubMed Web of Science ®Google Scholar
• DisisMLCheeverMAHER-2/neu protein: a target for antigen-specific immunotherapy of human cancerAdv Cancer Res1997713433719111870
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol200220371972611821453
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168410.1056/NEJMoa05212216236738
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167210.1056/NEJMoa05230616236737
   PubMed Web of Science ®Google Scholar
• GendlerSJCohenEPCrastonADuhigTJohnstoneGBarnesDThe locus of the polymorphic epithelial mucin (PEM) tumour antigen on chromosome 1q21 shows a high frequency of alteration in primary human breast tumoursInt J Cancer19904534314352307533
   PubMed Web of Science ®Google Scholar
• PattonSGendlerSJSpicerAPThe epithelial mucin, MUC1, of milk, mammary gland and other tissuesBiochim Biophys Acta1995124134074238547303
   PubMed Web of Science ®Google Scholar
• van der VegtBde RoosMAPeterseJLThe expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinomaHistopathology200751332233510.1111/j.1365-2559.2007.02757.x17645748
   PubMed Web of Science ®Google Scholar
• ZhangLConejo-GarciaJRKatsarosDIntratumoral T Cells, recurrence, and survival in epithelial ovarian cancerN Engl J Med2003348320321310.1056/NEJMoa02017712529460
   PubMed Web of Science ®Google Scholar
• von Mensdorff-PouillySVerstraetenAAKenemansPSurvival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucinJ Clin Oncol200018357458310653872
   PubMed Web of Science ®Google Scholar
• LiuJChenWSchwarerAPLiHTelomerase in cancer immunotherapyBiochimica et Biophysica Acta (BBA) – Reviews on Cancer [In Press]10.1016/j.bbcan.2009.09.001
   Google Scholar
• KimNPiatyszekMProwseKSpecific association of human telomerase activity with immortal cells and cancerScience199426651932011201510.1126/science.76054287605428
   PubMed Web of Science ®Google Scholar
• DomchekSMRecioAMickRTelomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillanceCancer Res20076721105461055510.1158/0008-5472.CAN-07-276517974999
   PubMed Web of Science ®Google Scholar
• PeoplesGEGurneyJMHuemanMTClinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patientsJ Clin Oncol200523307536754510.1200/JCO.2005.03.04716157940
   PubMed Web of Science ®Google Scholar
• PeoplesGEHolmesJPHuemanMTCombined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military cancer institute clinical trials group study I-01 and I-02Clin Cancer Res200814379780310.1158/1078-0432.CCR-07-144818245541
   PubMed Web of Science ®Google Scholar
• BenavidesLCGatesJDCarmichaelMGThe impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military cancer institute clinical trials group study I-01 and I-02Clin Cancer Res20091582895290410.1158/1078-0432.CCR-08-112619351776
   PubMed Web of Science ®Google Scholar
• NahtaRYuDHungMHortobagyiGNEstevaFJMechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer200635280 10.1038/ncponc0509
   Web of Science ®Google Scholar
• KoskiGKCohenPARosesREXuSCzernieckiBJReengineering dendritic cell-based anti-cancer vaccinesImmunol Rev200822225627610.1111/j.1600-065X.2008.00617.x18364007
   PubMed Web of Science ®Google Scholar
• CzernieckiBJKoskiGKKoldovskyUTargeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretionCancer Res20076741842185210.1158/0008-5472.CAN-06-403817293384
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumorsJ Natl Cancer Inst200092320521610.1093/jnci/92.3.20510655437
   PubMed Web of Science ®Google Scholar
• KnutsonKLSchiffmanKCheeverMADisisMLImmunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunityClin Cancer Res2002851014101812006513
   PubMed Web of Science ®Google Scholar
• DisisMLGooleyTARinnKGeneration of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccinesJ Clin Oncol200220112624263212039923
   PubMed Web of Science ®Google Scholar
• DisisMLCheeverMAHER-2/neu oncogenic protein: issues in vaccine developmentCrit Rev Immunol1998181–237459419446
   PubMed Web of Science ®Google Scholar
• SalazarLGCovelerALSwensenREKinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancersClin Immunol2007125327528010.1016/j.clim.2007.08.00617913588
   PubMed Web of Science ®Google Scholar
• DisisMLGrabsteinKHSleathPRCheeverMAGeneration of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccineClin Cancer Res1999561289129710389911
   PubMed Web of Science ®Google Scholar
• SalazarLGGoodellVO’MearaMPersistent immunity and survival after immunization with a HER2/neu (HER2) vaccineJ Clin Oncol (Meeting Abstracts)20092715S3010
   Google Scholar
• DisisMLWallaceDRGooleyTAConcurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancerJ Clin Oncol2009272810.1200/JCO.2008.20.6789
   Web of Science ®Google Scholar
• CovelerALGoodellVWebsterDJCommon adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunityBreast Cancer Res Treat200911319510010.1007/s10549-008-9910-y18236151
   PubMed Web of Science ®Google Scholar
• GoydosJSElderEWhitesideTLFinnOJLotzeMTA phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinomaJ Surg Res199663129830410.1006/jsre.1996.02648667619
   PubMed Web of Science ®Google Scholar
• ReddishMAMacLeanGDKogantyRRAnti-MUC-1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC-1 peptideInt J Cancer1998766817823http://dx.doi.org/10.1002/(SICI)1097-0215(19980610)76 :6%3C817::AID-IJC9%3E3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• DisisMLKnutsonKLMcNeelDGDavisDSchiffmanKClinical translation of peptide-based vaccine trials: the HER-2/neu modelCrit Rev Immunol2001211–326327311642608
   PubMed Web of Science ®Google Scholar
• DisisMLSchiffmanKGuthrieKEffect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein – based vaccineJ Clin Oncol200422101916192510.1200/JCO.2004.09.00515143085
   PubMed Web of Science ®Google Scholar
• ApostolopoulosVPieterszGATsibanisAPilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC-1 [ISRCTN71711835]Breast Cancer Res200683R2710.1186/bcr150516776849
   PubMed Web of Science ®Google Scholar
• BrossartPWirthsSStuhlerGReichardtVLKanzLBruggerWInduction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cellsBlood20009693102310811049990
   PubMed Web of Science ®Google Scholar
• PecherGHaringAKaiserLThielEMucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trialCancer Immunol Immunother20025111–1266967310.1007/s00262-002-0317-z12439613
   PubMed Web of Science ®Google Scholar
• VonderheideRHDomchekSMSchultzeJLVaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytesClin Cancer Res200410382883914871958
   PubMed Web of Science ®Google Scholar
• SalazarLGSlotaMWallaceDA phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancerJ Clin Oncol (Meeting Abstracts)200927Suppl 153054
   Web of Science ®Google Scholar
• SalazarLGCovelerAFintakPALow dose of a plasmid DNA vaccine encoding the HER-2/neu (HER2) intracellular domain (ICD) effectively stimulate tumor specific immunitySan Antonio Breast Cancer Symposium2006100Suppl1
   Google Scholar
• GulleyJLArlenPMTsangKYPilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinomaClin Cancer Res200814103060306910.1158/1078-0432.CCR-08-012618483372
   PubMed Web of Science ®Google Scholar
• CollinsRJrShpilbergODrobyskiWDonor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantationJ Clin Oncol1997152433444http://jco.ascopubs.org/cgi/content/abstract/15/2/4339053463
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839010.1056/NEJMoa070885718650514
   PubMed Web of Science ®Google Scholar
• VidalLGafter-GviliALeiboviciLRituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized TrialsJ Natl Cancer Inst2009101424825510.1093/jnci/djn478http://jnci.oxfordjournals.org/cgi/content/abstract/jnci;101/4/24819211444
   PubMedGoogle Scholar
• SlamonDJLeyland-JonesBShakSUse of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2N Engl J Med20013441178379210.1056/NEJM20010315344110111248153
   PubMed Web of Science ®Google Scholar
• CzernieckiBJRosesREKoskiGKDevelopment of vaccines for high-risk ductal carcinoma in situ of the breastCancer Res200767146531653410.1158/0008-5472.CAN-07-087817638860
   PubMed Web of Science ®Google Scholar